RhumbLine Advisers’s BridgeBio Pharma BBIO Stock Holding History
Bought
Maintained
Sold
Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2025
Q2 | $10.7M | Buy |
247,736
+27,608
| +13% | +$1.19M | 0.01% | 1028 |
|
2025
Q1 | $7.61M | Buy |
220,128
+1,008
| +0.5% | +$34.8K | 0.01% | 1141 |
|
2024
Q4 | $6.01M | Buy |
219,120
+5,007
| +2% | +$137K | 0.01% | 1333 |
|
2024
Q3 | $5.45M | Sell |
214,113
-7,290
| -3% | -$186K | ﹤0.01% | 1387 |
|
2024
Q2 | $5.61M | Buy |
221,403
+36,199
| +20% | +$917K | 0.01% | 1333 |
|
2024
Q1 | $5.73M | Buy |
185,204
+4,374
| +2% | +$135K | 0.01% | 1345 |
|
2023
Q4 | $7.3M | Buy |
180,830
+1,071
| +0.6% | +$43.2K | 0.01% | 1213 |
|
2023
Q3 | $4.74M | Buy |
179,759
+1,924
| +1% | +$50.7K | 0.01% | 1379 |
|
2023
Q2 | $3.06M | Buy |
177,835
+15,448
| +10% | +$266K | ﹤0.01% | 1669 |
|
2023
Q1 | $2.69M | Buy |
162,387
+4,448
| +3% | +$73.7K | ﹤0.01% | 1656 |
|
2022
Q4 | $1.2M | Buy |
157,939
+5,635
| +4% | +$42.9K | ﹤0.01% | 2037 |
|
2022
Q3 | $1.51M | Buy |
152,304
+11,293
| +8% | +$112K | ﹤0.01% | 1924 |
|
2022
Q2 | $1.28M | Buy |
141,011
+17,520
| +14% | +$159K | ﹤0.01% | 2019 |
|
2022
Q1 | $1.25M | Sell |
123,491
-3,841
| -3% | -$39K | ﹤0.01% | 2038 |
|
2021
Q4 | $2.12M | Sell |
127,332
-899
| -0.7% | -$15K | ﹤0.01% | 1845 |
|
2021
Q3 | $6.01M | Buy |
128,231
+1,755
| +1% | +$82.3K | 0.01% | 1248 |
|
2021
Q2 | $7.71M | Buy |
126,476
+22,957
| +22% | +$1.4M | 0.01% | 1168 |
|
2021
Q1 | $6.38M | Buy |
103,519
+11,525
| +13% | +$710K | 0.01% | 1267 |
|
2020
Q4 | $6.54M | Buy |
91,994
+577
| +0.6% | +$41K | 0.01% | 1197 |
|
2020
Q3 | $3.43M | Sell |
91,417
-21,815
| -19% | -$819K | 0.01% | 1387 |
|
2020
Q2 | $3.69M | Buy |
113,232
+7,986
| +8% | +$260K | 0.01% | 1382 |
|
2020
Q1 | $3.05M | Buy |
105,246
+77,018
| +273% | +$2.23M | 0.01% | 1314 |
|
2019
Q4 | $989K | Buy |
28,228
+3,696
| +15% | +$129K | ﹤0.01% | 2091 |
|
2019
Q3 | $527K | Buy |
+24,532
| New | +$527K | ﹤0.01% | 2297 |
|